You can bet at least a few pols will have Pfizer in their sights.
In the midst of plans to lower its U.S. tax liability by merging with a foreign company, the drug giant announced it will be raising prices for over 100 of its products, some by as much as 20 percent.
Reuters reports big price hikes for a number of high-profile drugs, based on a report by Wolters Kluwer, an international consulting firm.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
